A Multicenter, Double-blind, Randomized, Parallel Group Study to Assess the Effect of NCX4016 vs Placebo on Walking Distance in Patients With Peripheral Arterial Occlusive Disease at Leriche-Fontaine Stage II.
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2011
At a glance
- Drugs NCX 4016 (Primary)
- Indications Embolism and thrombosis; Peripheral arterial occlusive disorders
- Focus Therapeutic Use
- 18 Jan 2011 Last checked against ClinicalTrials.gov record.
- 07 Dec 2010 Official title, actual initiation date (September 2003) and trial investigator (Gresele P) added as reported by ClinicalTrials.gov.
- 07 Dec 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health [NCT01256775]).